Great question
I decided to use the dataset from ICIs, as it was much larger than that of OVs. Additionally, two phase III trials report pseudoprogression rates are similar between treatments (below). The larger phase III trial of T-Vec suggested the pseudoprogression rate was 14% in that trial, though I could not find where that was stated within the study itself. Thus, I went with 6% (5% if you take away SD from the ICI data), as this is where the majority of the data points.
Phase III trial of T-Vec (692 patients)
https://ascopubs.org/doi/full/10.1200/JCO.22.00343
Phase III trial of T-Vec (436 patients)
https://ascopubs.org/doi/10.1200/JCO.2014.58.3377
Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-241
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $80.20M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $342.6K | 922.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 138148 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 123242 | 2 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |